Copyright
©2010 Baishideng.
World J Gastrointest Pathophysiol. Jun 15, 2010; 1(2): 23-29
Published online Jun 15, 2010. doi: 10.4291/wjgp.v1.i2.23
Published online Jun 15, 2010. doi: 10.4291/wjgp.v1.i2.23
Table 1 DNA methylation profiles of cholangiocarcinoma varying with specific risk factors
| Methylated gene (proportion rate) | |
| Definite risk factors | |
| Primary sclerosing cholangitis | p16 (25%)[22] |
| Liver fluke infection (opisthorchis viverrini, or less frequently, clonorchis sinensis) | RUNX3 (49.1%)[70]; p14 (40.2%), p15 (48.9%), p16 (28.3%)[21]; hMLH1 (44.6%)[71] |
| Hepatolithiasis | p16 (100%[72], 54.6%[73]); TFF1 (37.5%)[74] |
| Biliary malformation (congenital choledochal cysts, caroli’s disease, etc) | NA |
| Thorotrast | hMLH1 (45.8%), hMSH2 (25.0%)[23] |
| Probable risk factors | |
| Hepatitis C or hepatitis B | NA |
| Cirrhosis | NA |
| Toxins (dioxin, polyvinyl chloride, nitrosamines, etc) | NA |
| Biliary-enteric anastomosis or cholangiojejunostomy | NA |
- Citation: Huang L, Frampton G, Liang LJ, DeMorrow S. Aberrant DNA methylation profile in cholangiocarcinoma. World J Gastrointest Pathophysiol 2010; 1(2): 23-29
- URL: https://www.wjgnet.com/2150-5330/full/v1/i2/23.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v1.i2.23